Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period at other companies

RBC Bearings logo
RBC BearingsRBC
46.1K+3.9%
General Motors logo
General MotorsGM
15M+29.3%
StoneX Group Inc. logo
StoneX Group Inc.SNEX
407.1K+71.3%
MSCI logo
MSCIMSCI
410K-15.5%
PPG Industries logo
PPG IndustriesPPG
714.1K+10.8%
Otis Worldwide logo
Otis WorldwideOTIS
1.9M+5.8%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, exercises in period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, exercises in period?
Jazz Pharmaceuticals (JAZZ) reported share-based compensation arrangement by share-based payment award, options, exercises in period of 658K in Q4 2025.
How has Jazz Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, exercises in period changed year-over-year?
Jazz Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, exercises in period increased by 4600.0% year-over-year, from 14K to 658K.
What does share-based compensation arrangement by share-based payment award, options, exercises in period mean?
The number of new shares created when employees exercise their stock options.
How do you interpret share-based compensation arrangement by share-based payment award, options, exercises in period?
An increase indicates higher employee participation in equity plans, which leads to share dilution.
How does share-based compensation arrangement by share-based payment award, options, exercises in period compare across companies?
Standard equity dilution metric; compared against total shares outstanding to assess dilution impact.